{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.1","value":"1.67"},{"groupId":"OG001","spread":"54.6","value":"1.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"PK parameters were calculated by standard non-compartmental analysis. Tmax is the time to reach maximum plasma concentration. Actual recorded sampling times were considered for the calculations.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)","id":"OG000","title":"HGG Cohort: Dabrafenib and Trametinib"},{"description":"Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)","id":"OG001","title":"LGG Cohort: Dabrafenib and Trametinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants who received at least one dose of trametinib with an evaluable Tmax PK parameter","reportingStatus":"POSTED","timeFrame":"Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose","title":"Tmax for Trametinib","type":"SECONDARY","unitOfMeasure":"hour"}